ZA200208307B - Oxadiazole derivatives having anticancer effects. - Google Patents

Oxadiazole derivatives having anticancer effects.

Info

Publication number
ZA200208307B
ZA200208307B ZA200208307A ZA200208307A ZA200208307B ZA 200208307 B ZA200208307 B ZA 200208307B ZA 200208307 A ZA200208307 A ZA 200208307A ZA 200208307 A ZA200208307 A ZA 200208307A ZA 200208307 B ZA200208307 B ZA 200208307B
Authority
ZA
South Africa
Prior art keywords
oxadiazole derivatives
anticancer effects
anticancer
effects
oxadiazole
Prior art date
Application number
ZA200208307A
Other languages
English (en)
Inventor
Takuyuki Yoshioka
Ryuji Maekawa
Fumihiko Watanabe
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of ZA200208307B publication Critical patent/ZA200208307B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ZA200208307A 2000-04-21 2002-10-15 Oxadiazole derivatives having anticancer effects. ZA200208307B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000120234 2000-04-21

Publications (1)

Publication Number Publication Date
ZA200208307B true ZA200208307B (en) 2003-10-15

Family

ID=18631080

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200208307A ZA200208307B (en) 2000-04-21 2002-10-15 Oxadiazole derivatives having anticancer effects.

Country Status (16)

Country Link
US (2) US6720343B2 (zh)
EP (1) EP1277744A4 (zh)
JP (1) JP3974781B2 (zh)
KR (1) KR100542780B1 (zh)
CN (1) CN1199956C (zh)
AU (2) AU4691601A (zh)
BR (1) BR0110211A (zh)
CA (1) CA2406685C (zh)
HU (1) HUP0300619A3 (zh)
MX (1) MXPA02010325A (zh)
NO (1) NO324868B1 (zh)
PL (1) PL203161B1 (zh)
RU (1) RU2275371C2 (zh)
TW (1) TWI294877B (zh)
WO (1) WO2001083463A1 (zh)
ZA (1) ZA200208307B (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
JPWO2005012268A1 (ja) 2003-07-30 2006-09-14 塩野義製薬株式会社 イソオキサゾール環を有するスルホンアミド誘導体
AU2005299851B2 (en) * 2004-10-22 2011-03-17 Merck Sharp & Dohme Corp. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
US7576222B2 (en) 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
RS20080525A (en) * 2006-05-09 2009-09-08 Pfizer Products Inc., Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
KR100783585B1 (ko) 2006-08-22 2007-12-07 한국생명공학연구원 스탯의 활성을 저해하는 옥사다이아졸 우레아 화합물을 유효성분으로 함유하는 암의 예방 또는 치료제
US8222243B2 (en) 2007-08-27 2012-07-17 Dart Neuroscience (Cayman) Ltd Therapeutic isoxazole compounds
CA2706834A1 (en) * 2007-12-10 2009-06-18 Actelion Pharmaceuticals Ltd Thiophene derivatives as agonists of s1p1/edg1
UY32858A (es) 2009-08-31 2011-03-31 Abbott Healthcare Products Bv Derivados de (tio)morfolina como moduladores de sip
TW201206893A (en) 2010-07-09 2012-02-16 Abbott Healthcare Products Bv Bisaryl (thio) morpholine derivatives as S1P modulators
TW201643169A (zh) 2010-07-09 2016-12-16 艾伯維股份有限公司 作為s1p調節劑的螺-哌啶衍生物
TWI522361B (zh) 2010-07-09 2016-02-21 艾伯維公司 作為s1p調節劑的稠合雜環衍生物
CN103450167A (zh) * 2012-05-28 2013-12-18 南京大学 一类含1,3,4-噁二唑和吡嗪环的酰腙类衍生物及其制备方法与用途
US10710994B2 (en) * 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
AU2020373047A1 (en) 2019-10-31 2022-05-19 ESCAPE Bio, Inc. Solid forms of an S1P-receptor modulator
CN113264899B (zh) * 2021-04-09 2022-06-14 台州学院 一种1，3，5-噁二嗪类化合物及其制备和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2207849C2 (ru) 1997-07-22 2003-07-10 Шионоги & Ко., Лтд. Композиция для лечения и профилактики гломерулопатии, новые соединения, в нее входящие, фармацевтическая композиция для ингибирования матриксных металлопротеиназ и композиция для ингибирования коллагеназ типа iv
AU5647099A (en) 1998-09-11 2000-04-03 Shionogi & Co., Ltd. Remedal or preventive agent for congestive heart failure

Also Published As

Publication number Publication date
BR0110211A (pt) 2003-06-03
KR100542780B1 (ko) 2006-01-11
WO2001083463A1 (fr) 2001-11-08
EP1277744A4 (en) 2007-07-11
PL203161B1 (pl) 2009-08-31
CA2406685C (en) 2006-10-31
TWI294877B (zh) 2008-03-21
US6720343B2 (en) 2004-04-13
RU2275371C2 (ru) 2006-04-27
JP3974781B2 (ja) 2007-09-12
EP1277744A1 (en) 2003-01-22
CN1436179A (zh) 2003-08-13
NO20025035D0 (no) 2002-10-18
PL359415A1 (en) 2004-08-23
US20040122066A1 (en) 2004-06-24
HUP0300619A3 (en) 2006-02-28
AU2001246916B2 (en) 2004-10-07
KR20030019357A (ko) 2003-03-06
CN1199956C (zh) 2005-05-04
HUP0300619A2 (hu) 2003-07-28
MXPA02010325A (es) 2003-04-25
NO20025035L (no) 2002-12-19
NO324868B1 (no) 2007-12-17
US20030203940A1 (en) 2003-10-30
CA2406685A1 (en) 2002-10-17
AU4691601A (en) 2001-11-12

Similar Documents

Publication Publication Date Title
ZA200300793B (en) Substituted-triazolopyrimidines as anticancer agents.
ZA200207331B (en) Ethylenediamine derivatives.
MXPA03002410A (es) 4-amino-quinazolinas.
ZA200000894B (en) 4-Phenyl-pyridine derivatives.
MXPA03004593A (es) Derivados de naftaleno.
ZA200201055B (en) Amino-triazolopyridine derivatives.
ZA200007669B (en) Insert.
ZA200101012B (en) Pharmaceutical combinations.
ZA200109595B (en) 13-methyl-erythromycin derivatives.
MXPA03002452A (es) Derivados de resorcinol.
ZA200208307B (en) Oxadiazole derivatives having anticancer effects.
HK1046411A1 (en) 5-Phenyl-pyrimidine derivatives.
EG23262A (en) Delta -pyrrolines.
MXPA02008907A (es) Capsulas.
AU2001246916A1 (en) Oxadiazole derivatives having anticancer effects
HK1056872A1 (en) Indoloquinazolinones.
MXPA03001591A (es) Derivados y analogos de 10-aril-11-h-benzo(b) fluorena para uso medicinal.
MXPA03001877A (es) 2-guanidin-4-arilquinazolinas.
MXPA03002668A (es) Guanidinas de sulfonilo.
MXPA03005714A (es) Sulfamidotienopirimidinas.
HK1050889A1 (en) Substituted aminomehyl-phenyl-cyclohexane derivatives.
HK1052925A1 (en) Substituted 1-aminobutan-3-ol derivatives.
MXPA03002411A (es) 4-amino-quinazolinas.
ZA200205482B (en) Aminosulfonylbiphenyl derivatives.
HK1050890A1 (en) Aminomethyl -phenyl-cyclohexanone derivatives.